Events

Rappel de Recharger

Selon U.S. Food and Drug Administration, ce/cet/cette rappel concerne un dispositif en/au/aux/à United States qui a été fabriqué par Medtronic Neuromodulation.

Qu'est-ce que c'est?

Une correction ou un retrait opéré par un fabricant afin de répondre à un problème causé par un dispositif médical. Les rappels surviennent lorsqu'un dispositif médical est défectueux, lorsqu'il pourrait poser un risque pour la santé, ou les deux à la fois.

En savoir plus sur les données ici
  • Type d'événement
    Recall
  • ID de l'événement
    75458
  • Classe de risque de l'événement
    Class 2
  • Numéro de l'événement
    Z-0700-2017
  • Date de mise en oeuvre de l'événement
    2016-10-03
  • Statut de l'événement
    Open, Classified
  • Pays de l'événement
    United States
  • Source de l'événement
    USFDA
  • URL de la source de l'événement
    https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?id=150430
  • Notes / Alertes
    U.S. data is current through June 2018. All of the data comes from the U.S. Food and Drug Administration, except for the category Manufacturer Parent Company.
    The Parent Company was added by ICIJ.
    The parent company information is based on 2017 public records.
  • Notes supplémentaires dans les données
    Stimulator, electrical, implanted, for parkinsonian tremor - Product Code MHY
  • Cause
    Medtronic has identified an increased number of complaints from customers involving reports of rechargers (medtronic model 37751 recharger, which is included in models 37754 and 97754 charging systems,spinal cord stimulation)that are in an unresponsive error state, where the recharger is non-functional with a blank display screen and is beeping every 5 seconds. medtronic has determined all rechargers manufactured starting in november 2014 (indicated by serial numbers beginning with nka4 or nku4) are more susceptible to this error state.
  • Action
    Consignees were sent a series of documents which included an introductory Medtronic and "Urgent Medical Device Correction" letters dated September 2016. The urgent letters included one for Deep Brain Stimulation (DBS) and one for Spinal Cord Stimulation(SCS) . Each letter was addressed to Healthcare Professional. Only physicians associated with both SCS and DBS therapy received the cover letter. The letters provided information on "Background, Issues Mitigation, Recommendation, Additional Information and Patient Notification (DBS). Requested consignees to complete and return the Physician /HCP Reply Form. For questions contact Medtronic Technical Services at 1-800-707-0933 weekdays 7 am to 6pm, CT.

Device

Recharger
  • Modèle / numéro de série
    serial numbers beginning with NKA4 or NKU4
  • Classification du dispositif
    Neurological Devices
  • Classe de dispositif
    3
  • Dispositif implanté ?
    Yes
  • Distribution
    Worldwide Distribution - US Nationwide including DC OUS: Canada and others.
  • Description du dispositif
    Model 37751 Recharger || Product Usage: || The Medtronic 37751 Recharger is a hand-held device used to charge the battery in a patient s neurostimulator. It includes a display to provide information on the charging system. The charging system consists of the Model 37751 Recharger, an AC power supply and power cord (Model 37761) and an antenna.
  • Manufacturer
    Medtronic Neuromodulation

Manufacturer

Medtronic Neuromodulation
  • Adresse du fabricant
    Medtronic Neuromodulation, 7000 Central Ave, Minneapolis MN 55421-1241
  • Société-mère du fabricant (2017)
    Medtronic plc
  • Commentaire du fabricant
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source
    USFDA